Phase II Study of First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Latest Information Update: 21 May 2024
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 16 May 2024 Planned End Date changed from 1 Oct 2025 to 1 Jun 2027.
- 05 Mar 2024 Planned End Date changed from 1 May 2024 to 1 Oct 2025.
- 05 Mar 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Jun 2025.